Quick Answer
ARS Pharmaceuticals, Inc. reported Stockholders Equity of $114.26 million for the year ending 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -55.5% in Stockholders Equity from 2024 to 2025.
- This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$64.00 million | Q2 2020: -$70.34 million | Q3 2020: -$78.25 million | Q1 2021: $368.55 million | Q2 2021: $349.65 million | Q3 2021: $332.13 million | Q1 2022: -$38.26 million | Q2 2022: -$44.03 million | Q3 2022: -$50.16 million | Q1 2023: $261.16 million | Q2 2023: $248.55 million | Q3 2023: $237.28 million | Q1 2024: $223.87 million | Q2 2024: $215.24 million | Q3 2024: $200.98 million | Q1 2025: $228.97 million | Q2 2025: $192.32 million | Q3 2025: $147.66 million.
- Over the full 7 years of available data (2019 to 2025), ARS Pharmaceuticals, Inc.'s Stockholders Equity has grown by 294.4%.
- Historical annual values: Fiscal year 2025: $114.26 million | Fiscal year 2024: $256.80 million | Fiscal year 2023: $230.76 million | Fiscal year 2022: $272.89 million | Fiscal year 2021: -$31.27 million | Fiscal year 2020: -$14.05 million | Fiscal year 2019: -$58.78 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: